Rick Kapur: Current Understanding of FNAIT Regarding Diagnostics, Pathophysiology and Management
Rick Kapur, Research Group Leader at Sanquin, Principal Investigator at Amsterdam UMC shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood, adding:
“Happy to see this paper out where we highlight our current understanding of Fetal-neonatal alloimmune thrombocytopenia (FNAIT) regarding diagnostics, pathophysiology and management.
New developments support the importance of identifying predictive biomarkers of fetal risk to guide antenatal management and of preventing affected pregnancies ideally by screening all pregnancies followed by prophylaxis.
With James Bussel and Jory Hirshman.
Free access till August 14.”
Title: Anti–HPA-1a fetal-neonatal alloimmune thrombocytopenia: reframing diagnostics, pathophysiology, and management
Authors: James B. Bussel, Jory M. Hirshman, Rick Kapur

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?
-
Nov 15, 2026, 15:53Nicolas Schommer: The Seed and Soil Hypothesis of NET-Mediated Inflammation
-
Nov 15, 2026, 15:36Giovanni Merlino: Targeting LDL-C to Prevent Recurrent Stroke
-
Nov 15, 2026, 15:33Riitta Lassila: From Helsinki to ISTH 2027 Advancing Thrombosis Research
-
Nov 15, 2026, 15:30Andreas Calatzis: Can Protein C and Plasma Overcome Fibrinolysis Resistance in Sepsis?
-
Nov 15, 2026, 15:25Hussnain Javaid: Thalassaemia 2026 New Therapies Transforming UK Practice